Neuroblastoma

Shohet, Jason M.; Foster, Jennifer

doi:10.1136/bmj.j1863

Cited by 43 publications

(54 citation statements)

References 43 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroblastoma, originating from the developing sympathetic nervous system, is the most common extracranial tumor of infancy and childhood. The median age at diagnosis is approximately 18 months [ 1 ]. It is a fatal solid cancer accounting for approximately 8–10% of all childhood malignancies [ 1 – 3 ] and contributes to approximately 10–15% of all cancer-related deaths in children [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…The median age at diagnosis is approximately 18 months [ 1 ]. It is a fatal solid cancer accounting for approximately 8–10% of all childhood malignancies [ 1 – 3 ] and contributes to approximately 10–15% of all cancer-related deaths in children [ 4 ]. Despite intensive multimodal treatments [ 5 ], 5-year event-free survival for high-risk (approximately 50% of all cases) neuroblastoma patients remains less than 50% [ 6 , 7 ], and the 5-year survival rate for all neuroblastoma patients is approximately 50% [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population

et al. 2018

View full text Add to dashboard Cite

Neuroblastoma, which accounts for approximately 10% of all pediatric cancer-related deaths, has become a therapeutic challenge and global burden attributed to poor outcomes and mortality rates of its high-risk form. Previous genome-wide association studies (GWASs) identified the LINC00673 rs11655237 C>T polymorphism to be associated with the susceptibility of several malignant tumors. However, the association between this polymorphism and neuroblastoma susceptibility is not clear. We genotyped LINC00673 rs11655237 C>T in 393 neuroblastoma patients in comparison with 812 age-, gender-, and ethnicity-matched healthy controls. We found a significant association between the LINC00673 rs11655237 C>T polymorphism and neuroblastoma risk (TT compared with CC: adjusted odds ratio (OR) =1.80, 95% confidence interval (CI) =1.06–3.06, P=0.029; TT/CT compared with CC: adjusted OR =1.31, 95% CI =1.02–1.67, P=0.033; and T compared with C: adjusted OR =1.29, 95% CI =1.06–1.58, P=0.013). Furthermore, stratified analysis indicated that the rs11655237 T allele carriers were associated with increased neuroblastoma risk for patients with tumor originating from the adrenal gland (adjusted OR =1.51, 95% CI =1.06–2.14, P=0.021) and International Neuroblastoma Staging System (INSS) stage IV disease (adjusted OR =1.60, 95% CI =1.12–2.30, P=0.011). In conclusion, we verified that the LINC00673 rs11655237 C>T polymorphism might be associated with neuroblastoma susceptibility. Prospective studies with a large sample size and different ethnicities are needed to validate our findings.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Due to the aggressive and unpredictable nature of high-risk and recurrent neuroblastoma, recent work has focused on the development of new therapeutic techniques [12]. The multitude of new therapies include cytotoxic agents, targeted agents, immunotherapy, retinoids, angiogenesis inhibitors, tyrosine kinase inhibitors, as well as other approaches [12]. One approach that has been of little focus in pediatric neuroblastoma research is the use of nitric oxide (NO) as an anticancer agent [20,21].…”

mentioning

confidence: 99%

Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells

Gordon

Reynolds

Brown

2020

Veterinary Sciences

View full text Add to dashboard Cite

Neuroblastoma, the most common extracranial solid tumor in children, accounts for 15% of all pediatric cancer deaths. Pharmaceutical applications of S-Nitrosylation, which, under normal conditions is involved with a host of epigenetic and embryological development pathways, have exhibited great potential for use as adjuvant therapeutics in the clinical management of cancer. Herein, an evaluation of the impact of nitric oxide (NO) as a potent anticancer agent on murine neuroblastoma cells is presented. Excitingly cell viability, colony formation, and non-carcinogenic cell analysis illustrate the significance and practicality of NO as a cytotoxic anticancer therapeutic. Resazurin, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt), and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphyltetrazolium bromide) assays consistently displayed a moderate,~20-25% reduction in cell viability after exposure to 1 mM S-Nitrosoglutathione (GSNO). A colony formation assay demonstrated that treated cells no longer exhibited colony formation capacity. Identically GSNO-treated Adult Human Dermal Fibroblasts (HDFa) exhibited no decrease in viability, indicating potential discrimination between neoplastic and normal cells. Collectively, our findings indicate a potential application for NO as an adjuvant therapeutic in the clinical management of neuroblastoma. Vet. Sci. 2020, 7, 51 2 of 15 and intricacy of disease progression and response to treatment, the International Neuroblastoma Staging System (INSS) was developed to classify the extent of the disease and impact the treatment approach [13]. Three distinct stages comprise the INSS: low, intermediate, and high risk. Each risk group is comprised of definitions containing the stage(s), patient age, presence/absence of the MYCN gene, histology, and DNA ploidy. Currently, low risk tumors represent ≤25% of initial diagnoses, intermediate risk represent about~15% of initial diagnoses, and high risk tumors are the most commonly diagnosed, at ≥60% [11]. In patients with low risk disease, surgery and observation are the central therapeutic options that contribute to >90% survival [14,15]. Patients with intermediate risk disease typically receive a variety of sequential treatments including chemotherapy, surgery, and radiation therapy, if necessary. Survival rates in this group drop some but remain favorable at >80% [16,17]. High risk treatment protocols commence in an identical manner and additional treatments are frequently required, such as immunotherapy and bone marrow transplant. Despite the advances in treatments for low and intermediate risk disease, patients with high risk disease continue to face particularly poor prognosis, with~40% five-year overall survival rates [18,19]. Overall relapse rates are additionally overwhelming, at >60% [12]. In a similar fashion, treatments for recurrent low-risk and intermediate-risk disease are largely effective. However, recurrent high-risk neuroblastoma remains a significant challenge. Due to the a...

show abstract

“…Neuroblastoma is an embryonic malignancy deriving from neural crest cells that undergo rapid differentiation during fetal development. As the transition from normal to malignant tissue can occur in multiple steps, its phenotype is highly heterogeneous [1]. Although progress has been made in the treatment of neuroblastoma, the outcome of children at high risk remains poor with a long-term survival as low as 50 % [2].…”

Section: Introductionmentioning

confidence: 99%

CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma

et al. 2019

View full text Add to dashboard Cite

AbstractBackgroundNeural cell adhesion molecules like close homolog of L1 protein (CHL1) and neuronal glia related cell adhesion molecule (NrCAM) play an important role in development and regeneration of the central nervous system. However, they are also associated with cancerogenesis and progression in adult malignancies, thus gain increasing importance in cancer research. We therefore studied the expression of CHL1 and NrCAM according to the course of disease in children with neuroblastoma.MethodsCHL1 and NrCAM expression levels were histologically assessed by tissue microarrays from surgically resected neuroblastoma specimens of 56 children. Expression of both markers was correlated to demographics as well as clinical data including metastatic dissemination and survival.ResultsCHL1 was expressed in 9% and NrCAM in 51% of neuroblastoma tissue samples. Expression of CHL1 was higher in patients with low Hughes grade 1a/b (p=0.01). NrCAM was more often detected in patients with a low International Staging System (INSS) score 1/2 (p=0.04).ConclusionCHL1 and NrCAM expression was associated with low-grade pediatric neuroblastoma. These adhesion molecules may play a role in early tumor development of neuroblastoma.

show abstract

Neuroblastoma

Cited by 43 publications

References 43 publications

LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population

LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population

Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells

CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma

Contact Info

Product

Resources

About

Neuroblastoma

Cited by 43 publications

References 43 publications

LINC00673 rs11655237 C&gt;T confers neuroblastoma susceptibility in Chinese population

LINC00673 rs11655237 C&gt;T confers neuroblastoma susceptibility in Chinese population

Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells

CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma

Contact Info

Product

Resources

About

LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population

LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population